1)Fuster V, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 123: e269-367.
2)JCS Joint Working Group. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). Circ J. 2014; 78: 1997-2021.
3)Akao M, et al. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J. 2014; 78: 2166-2172.
4)Inoue H, et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. Circ J. 2013; 77: 2264-2270.
5)Matsumoto M, et al. Relationship Between Infarct Volume and Prothrombin Time-International Normalized Ratio in Ischemic Stroke Patients With Nonvalvular Atrial Fibrillation. Circ J. 2017; 81: 391-396.
6)日本循環器学会/日本不整脈心電学会.2020年改訂版 不整脈薬物治療ガイドライン.https://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf(2023年6月アクセス)
7)Morgan CL, et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res. 2009; 124: 37-41.
8)Giugliano RP, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093-2104.
9)Baillargeon J, et al. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med. 2012; 125: 183-189.
10)Garcia DA, Crowther MA. Reversal of warfarin: case-based practice recommendations. Circulation 2012; 125: 2944-2947.